{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (3β)-''N''-Ethyl-''N'',''N''-dimethylcona-4,6-dienin-3-aminium iodide
| image = Stercuronium iodide.png
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 30033-10-4
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 71924
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 64935
| UNII = K1477R7DDR
| KEGG = 
| ChEBI = 
| ChEMBL = 

<!--Chemical data-->
| C=26 | H=43 | I=1 | N=2
| molecular_weight = 510.548 g/mol
| SMILES = CC[N+](C)(C)[C@H]1CC[C@@]2([C@H]3CC[C@]45CN([C@H]([C@H]4CC[C@H]5[C@@H]3C=CC2=C1)C)C)C.[I-]
| StdInChI_Ref = 
| StdInChI = 1S/C26H43N2.HI/c1-7-28(5,6)20-12-14-25(3)19(16-20)8-9-21-23(25)13-15-26-17-27(4)18(2)22(26)10-11-24(21)26;/h8-9,16,18,20-24H,7,10-15,17H2,1-6H3;1H/q+1;/p-1/t18-,20-,21+,22+,23-,24-,25-,26-;/m0./s1
| StdInChIKey_Ref = 
| StdInChIKey = NZMZXOUHSHDAQQ-VIGAWJBNSA-M
| synonyms = MYC-1080; MYSC-1080
}}

'''Stercuronium iodide''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code names '''MYC-1080''', '''MYSC-1080''') is an [[aminosteroid]] [[neuromuscular blocking agent]] which was never marketed.<ref name="Kar2005">{{cite book|author=Ashutosh Kar|title=Medicinal Chemistry|url=https://books.google.com/books?id=07g30rxCA0EC&pg=PA175|year=2005|publisher=New Age International|isbn=978-81-224-1565-0|pages=175–}}</ref><ref name="BowdenCollier2013">{{cite book|author1=R.E.M. Bowden|author2=B. Collier|author3=R.D. Dripps|author4=L.W. Duchen|author5=G.E. Hale Enderby|author6=B.L. Ginsborg|author7=S. Head|author8=F. Hobbiger|author9=D.H. Jenkinson|author10=F.C. MacIntosh|author11=S.E. Smith|title=Neuromuscular Junction|url=https://books.google.com/books?id=D-DtCAAAQBAJ&pg=PA421|date=13 March 2013|publisher=Springer Science & Business Media|isbn=978-3-642-45476-9|pages=421–}}</ref> It acts as a [[competitive antagonist]] of the [[nicotinic acetylcholine receptor]] (nAChR), and is also reported to be an [[acetylcholinesterase inhibitor]].<ref name="Kar2005" />

==References==
{{Reflist|2}}


{{Muscle relaxants}}
{{Acetylcholine metabolism and transport modulators}}
{{Nicotinic acetylcholine receptor modulators}}

[[Category:Acetylcholinesterase inhibitors]]
[[Category:Muscle relaxants]]
[[Category:Nicotinic antagonists]]
[[Category:Quaternary ammonium compounds]]


{{steroid-stub}}
{{musculoskeletal-system-drug-stub}}